Valley Forge Investment Corporation led a $25m round in Vittoria Biotherapeutics.

Valley Forge Investment Corporation, a US-based investment firm, led a $25m round in Vittoria Biotherapeutics, a clinical-stage cell therapy company developing novel autologous T-cell therapies. “This milestone represents a vote of confidence from both our existing and new investors, and reinforces our commitment to pioneering innovative immunotherapies. This capital infusion will accelerate the clinical progression of VIPER-101, and we are excited to explore its potential to deliver meaningful therapeutic benefits to patients battling T-cell Lymphoma,” Dr. Nicholas Siciliano, Vittoria Biotherapeutics Chief Executive Officer.